SCHEMBL1069807

SCHEMBL1069807

CCC1(c2ccccc2)CCC(=O)N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.49
TACR3 P29371 1/20 0.49
TSHR P16473 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 1/20 0.39
CYP19A1 P11511 4/20 0.39
CYP3A4 P08684 2/20 0.39
CYP17A1 P05093 1/20 0.39
CYP11A1 P05108 1/20 0.39
TBXAS1 P24557 1/20 0.39
PMP22 Q01453 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE3A Q14432 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31327704 0.83 TACR1 (0.46) TACR1TACR3TSHRMEN1KMT2A
SCHEMBL28542067 0.77 MAPT (0.38) TACR1TACR3TSHRMEN1KMT2A
SCHEMBL29976392 0.77 MAPT (0.38) TACR1TACR3TSHRMEN1KMT2A
SCHEMBL18150842 0.74 MEN1 (0.44) TACR1TACR3MEN1KMT2ACYP2C9
SCHEMBL8675184 0.72 TACR1 (0.39) TACR1TACR3MEN1KMT2ACYP2C9
SCHEMBL3007339 0.72 CYP2C9 (0.45) TACR1TACR3TSHRMEN1KMT2A
SCHEMBL17857588 0.72 CYP1A2 (0.43) TSHRMEN1KMT2ACYP1A2POLB
SCHEMBL11846334 0.71 TSHR (0.44) TSHRMEN1KMT2ACYP1A2POLB
Glutethimide SCHEMBL113709 0.71 CYP19A1 (0.72) CYP1A2CYP19A1CYP3A4CYP17A1CYP11A1
Glutethimide SCHEMBL21119240 0.71 CYP19A1 (0.72) CYP1A2CYP19A1CYP3A4CYP17A1CYP11A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4129652-A CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1978-12-12 US claimed
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2025-10-02 US disclosed
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures UNIVERSITY OF HOUSTON SYSTEM (US) 2025-07-15 US disclosed
US-20230414566-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2023-12-28 US disclosed
US-11806333-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures UNIVERSITY OF HOUSTON SYSTEM (US) 2023-11-07 US disclosed
US-20200360342-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2020-11-19 US disclosed
EP-2275143-B1 Conjugates of perphenazine or fluphenazine with carboxylic acids UNIV RAMOT (IL) 2012-12-19 EP disclosed
US-20120309748-A1 CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF BAR-ILAN UNIVERSITY (IL) 2012-12-06 US disclosed
US-8283381-B2 Conjugated psychotropic drugs and uses thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-10-09 US disclosed
US-8168628-B2 Conjugated psychotropic drugs and uses thereof RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-05-01 US disclosed
EP-1429844-A2 CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF Ramot at Tel Aviv University Ltd. (IL) 2004-06-23 EP disclosed
WO-2003026563-A9 CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF UNIV RAMOT (IL) 2004-04-22 WO disclosed
WO-2003026563-A2 CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2003-04-03 WO disclosed
US-20020173537-A1 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITAET (DE) 2002-11-21 US disclosed
US-6384069-B1 BRAIN DISORDERS CHRONIC PAIN, HYPOGLYCEMIA, HYPOXIA, TRAUMA, ALZHEIMER'S DISEASE, AIDS-ASSOCIATED DEMENTIA, AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON'S DISEASE, AND CHRONIC ALCOHOLISM, COMPRISING ADMINISTERING TO A PATIENT IN NEED A KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITAET (DE) 2002-05-07 US disclosed
US-5463125-A 3-hydroxy-3-phenylpentamide SANDOVAL GUILLERMO C (MX) 1995-10-31 US disclosed
US-4138484-A CHLORPROMAZINE OR THORIDAZINE WITH G-HYDROXYBUTYROLACTONE NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1979-02-06 US disclosed
US-4129652-A CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1978-12-12 US disclosed
US-4084000-A NEUROLEPTIC, GAMMA-AMINOBUTYRIC ACID DERIVATIVES NELSON RESEARCH AND DEVELOPMENT COMPANY (US) 1978-04-11 US disclosed
US-3978216-A AMINOOXYACETIC ACID NELSON RESEARCH & DEVELOPMENT COMPANY (US) 1976-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360342-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 TACR1 3742/4885TACR3 3549/4885TSHR 3185/4885
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures AADAC, GABRB2, GABARAPL2 TACR1 3742/4885TACR3 3549/4885TSHR 3185/4885
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 TACR1 3742/4885TACR3 3549/4885TSHR 3185/4885
US-20230414566-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 TACR1 3742/4885TACR3 3549/4885TSHR 3185/4885
US-20020173537-A1 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level GRM1, GRM2, GRIN2A TACR1 1656/4885TACR3 4453/4885TSHR 1693/4885
US-11806333-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures AADAC, GABRB2, GABARAPL2 TACR1 3742/4885TACR3 3549/4885TSHR 3185/4885
US-20120309748-A1 CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF SLC18A2, SLC6A3, SLCO1B3 TACR1 320/4885TACR3 1438/4885TSHR 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.